BCM
TAK icon

Bluefin Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Bluefin Capital Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-688,000
Closed -$230K – 467
2019
Q1 		$230K Buy
688,000
+678,000
+6,780% +$13.6M 0.03% 203
2018
Q4 		$13K Buy
+10,000
New +$169K ﹤0.01% 373

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Bluefin Capital Management's TAK Position: Q2 2026 in Review

Bluefin Capital Management sold out of Takeda Pharmaceutical (TAK) in Q2 2026, closing a stake of 10,900 shares — an estimated $202K sold.

Bluefin Capital Management first reported a position in TAK in Q1 2019 and held it in 4 quarters. The position peaked at $24.5M in Q1 2019. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Bluefin Capital Management reported no remaining Takeda Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Bluefin Capital Management sold 10,900 Takeda Pharmaceutical shares in Q2 2026, an estimated $202K.
  • Bluefin Capital Management first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 4 quarters.
  • Bluefin Capital Management's Takeda Pharmaceutical position peaked at $24.5M in Q1 2019.
  • 378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Bluefin Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.